Latest stories on LPCN
Lipocine Updates Investor Presentation to Reflect Strategy
TipRanks52 · neutralproduct/pr
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
3 Penny Stocks to Watch Today, October 8
TipRanks50 · neutralgeneral
Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
InvestorsHub63 · neutralproduct/pr
Lipocine stock surges 30% on Health Canada drug approval
Investing.com Markets78 · bullishproduct/pr
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
Stocktwits News73 · bullishproduct/pr
Lipocine’s TLANDO Wins Health Canada Approval, Setting Up a Canadian Launch by Year-End 2026
October 7, 2026
MarketChameleon73 · bullishproduct/pr
Lipocine announces Health Canada approved TLANDO capsules
The Fly63 · neutralgeneral
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
PR Newswire73 · bullishproduct/pr
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine stock price target maintained at $4 by H.C. Wainwright
Investing.com Analyst Ratings56 · neutralanalyst
H.C. Wainwright sets $4 price target on Lipocine
The Fly56 · neutralanalyst
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine initiates Phase 3 study of LPCN 1154 for postpartum depression
The Fly59 · neutralproduct/pr
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
PR Newswire63 · neutralproduct/pr
Lipocine Launches Phase 3 BLOOM Study for PPD
TipRanks56 · neutralproduct/pr
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine Updates Sales Agreement Fee Structure with A.G.P.
TipRanks50 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
PR Newswire55 · neutralgeneral
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
8-K/A - Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral
Lipocine GAAP EPS of -$0.32, revenue of $190M
Seeking Alpha34 · bearishearnings
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
PR Newswire50 · neutralearnings
Lipocine Inc. (LPCN) files 8-K
SEC 8-K50 · neutralgeneral